Jaguar Health, Inc.
JAGX
|
News
|
$0.1604
-4.52%
26M
|
Health Technology
(0.0% 1d) (135.5% 1m) (-64.4% 1y) (0.0% 2d) (-5.6% 3d) (-5.6% 7d) (-62.57% volume)
Earnings Calendar: 2023-11-14
Market Cap: $ 44,305,088
http://www.jaguar.health
Sec Filling | Patents | 29 employees
(US) Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
diarrhea hiv gastrointestinal animals
add to watch list Paper trade email alert is off
Press-releases
Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
JAGX | News | $0.1604 -4.52% 26M
|
Health Technology
|
| O: 6.25%
H: 17.65%
C: 5.88%
health congress cancer care family
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
JAGX | News | $0.1604 -4.52% 26M
|
Health Technology
|
| O: 26.26%
H: 73.2%
C: 18.87%
health cancer care for commercial
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Published: 2024-04-08 (Crawled : 14:00) - biospace.com/
JAGX | News | $0.1604 -4.52% 26M
|
Health Technology
|
| O: 7.14%
H: 1.11%
C: -8.89%
health granted extension
Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
Published: 2024-04-02 (Crawled : 14:00) - biospace.com/
JAGX | News | $0.1604 -4.52% 26M
|
Health Technology
|
| O: -4.68%
H: 0.82%
C: 0.82%
health international
Jaguar Health Reports 2023 Financial Results
Published: 2024-04-01 (Crawled : 18:00) - biospace.com/
JAGX | News | $0.1604 -4.52% 26M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -14.35%
health financial results
Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
Published: 2024-02-14 (Crawled : 15:00) - biospace.com/
JAGX | News | $0.1604 -4.52% 26M
|
Health Technology
|
| O: -0.24%
H: 1.1%
C: -0.73%
health direct
Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
Published: 2024-02-12 (Crawled : 14:30) - biospace.com/
JAGX | News | $0.1604 -4.52% 26M
|
Health Technology
|
| O: 6.09%
H: 7.88%
C: 0.68%
fda drug diarrhea health designation application crofelemer submission
Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
Published: 2024-01-29 (Crawled : 15:00) - biospace.com/
JAGX | News | $0.1604 -4.52% 26M
|
Health Technology
|
| O: -3.2%
H: 0.37%
C: -4.13%
conference health microcap
A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
Published: 2023-12-11 (Crawled : 20:00) - biospace.com/
JAGX | News | $0.1604 -4.52% 26M
|
Health Technology
|
| O: -15.16%
H: 1.78%
C: -18.62%
diarrhea cancer trial therapy
Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
JAGX | News | $0.1604 -4.52% 26M
|
Health Technology
|
| O: 0.03%
H: 1.67%
C: -1.27%
breast health life symposium cancer pharmaceuticals family study
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 55% | 45% |
Top 10 Gainers
CZOO | $10.52 110.82% 10M
|
CSSE 4 | $0.3181 108.86% 170M
|
Consumer Services
BOF | $1.88 60.68% 98M
|
AMST | $3.1 55.0% 66M
|
Technology Services
LICN | $0.8592 53.43% 13M
|
WIMI | $1.03 41.99% 15M
|
Technology Services
MULN | News | $3.675 34.62% 11M
|
Information
RILY | $28.605 31.7% 9.9M
|
Finance
RBBN 4 | $3.305 28.6% 1.9M
|
Electronic Technology
RCAT | $1.53 27.5% 2.9M
|
Information
Last 48 Hours Insiders Buying
NWFL | News | $24.0 -0.46% 4.6K
|
Finance
|
17:00
MNSB P 310 | $15.91 -2.75% 18K
|
Finance
|
15:30
TPL P 3 | $585.605 -0.38% 11K
|
Miscellaneous
|
15:01
ISBA P 966 | $18.0001 3.1K
|
Finance and Insurance
|
15:01
MEGI | $11.98 74K
|
|
00:30
CTRN P 29000 | $21.855 -1.69% 26K
|
Retail Trade
|
22:00
CONN | $3.735 0.95% 21K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.685 6.6K
|
Utilities
|
18:30
CMTV P 700 | $16.59 1K
|
Finance and Insurance
|
18:30
FNB | $13.56 -0.51% 420K
|
Finance
|
17:30
RMCF | $3.54 2.5K
|
Consumer Non-Durables
|
20:10